EZH2 and nasopharyngeal carcinoma: NPC progression known to be associated with Epstein-Barr Virus-encoded latent membrane protein 1 (LMP1) also drives expression of EZH2 in activated Treg cells, which was antagonized by treatment with Dznep, leading to depletion of Treg cells and enhanced anti-tumor immunity.